Engineering evaluation: the reported issue, related to the balloon not maintaining its shape during deployment, was confirmed during evaluation.This is considered to be related to the bunching and the hole observed at the proximal end of the balloon.The reported migration, could not be independently confirmed with the available information.Cbas® heparin surface incorporates carmeda heparin manufactured from heparin sodium api, which is covalently bound to the device surface and is essentially non-eluting.W.L.Gore & associates, inc.(gore) is submitting this report to comply with 21 c.F.R.Part 803, the medical device reporting regulation.This report is based upon information obtained by gore, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Blank fields present on this report include required fields and fields determined to be not applicable.Blank required fields indicate that the information was not provided, was deemed unavailable or was not applicable.This report does not constitute an admission or a conclusion by fda, gore, or its associates that the device, gore or its associates caused or contributed to the event described in the report.In particular, this report does not constitute a legal admission by anyone that the product described in this report has any defects or has malfunctioned, as defined from a legal standpoint.These words are included in the report and are fixed items for selection created by the fda, to categorize the type of event solely for the purpose of reporting pursuant to part 803.This statement should be included with any information or report disclosed to the public under the freedom of information act.
|
On (b)(6) 2022, the patient underwent treatment for an aortic aneurysm repair in the renal artery using a gore® viabahn® vbx balloon expandable endoprosthesis as a part of a fenestrated endograft.The physician stated the fenestrated main body was a modified cook endograft.The vbx device was advanced over a rosen wire through a tourguide sheath into the renal artery.During inflation of the vbx device it was reported the balloon lost its uniform shape.The distal end deflated and the proximal end enlarged.The balloon was deflated and withdrawn from the patient.It was reported the endoprosthesis was fully deployed.However, upon final imaging it was identified that the endoprosthesis moved further into the renal artery.An additional gore® viabahn® vbx balloon expandable endoprosthesis was implanted to bridge the vbx device in the renal artery to the fenestrated endograft system.The patient tolerated the procedure.
|